In January, pharmaceutical investment returned to normal, and the pharmaceutical sector of Hong Kong stocks recovered, and many stocks rose sharply

【Pharmaceutical Network Pharmaceutical Stock Market】 The agency said that looking forward to January 2023, investment will return to normal, and recovery and new medical infrastructure after the liberalization of prevention and control will be the main line
.
Optimistic about the three major sectors of medical care: (1) the pharmaceutical consumer industry with recovered demand, optimistic about the large space for clinical demand; (2) the innovative drug sector that benefits with the recovery of the volume of diagnosis and treatment; (3) Optimistic about the medical equipment sector that benefits from new medical infrastructure and fiscal discount policies
.
On January 3, the pharmaceutical sector of Hong Kong stocks recovered, with Akeso Biotech rising 6.
74%, Keji Pharmaceutical rising 6.
01%, Shandong Xinhua Pharmaceutical rising by more than 7%, InnoCare and Federal Pharmaceutical rising by more than 5%.

In addition, the Hang Seng Medical ETF fluctuated to the upside, rising 0.
67%, with a turnover of more than 600 million yuan, and active intraday trading
.
It is reported that Akeso Biologics strengthened this morning, rising about 7%, hitting a new high
since December.
On the news, a few days ago, First Shanghai released an update report on Akeso, saying that the commercialization of Kaitanil is progressing smoothly, and Anico's sales have grown
steadily.
If Kaitani successfully enters the medical insurance through negotiation, the sales volume can be expected
.
AK112 refreshed the transaction
amount record of China's biotech innovative drugs.
Once the head-to-head clinical data of AK112 and K drugs wins, it is expected to shake the global hegemony of K drugs and form a dimensionality reduction blow to PD-1 drugs, and the global potential market space of AK112 is very large
.
Maintain "Buy" rating with a target price of HK$
50.
05.
According to the data, Akeso Biopharma is a biopharmaceutical company
dedicated to the research, development, production and commercialization of innovative antibody new drugs.
As of June 30, 2022, Akeso has more than 30 innovative projects covering oncology, autoimmune and metabolic diseases
.
In the field of tumor immunotherapy, Akeso's products undergoing clinical trials include Kaitanil (Cardunilib, PD-1/CTLA-4), Anicor (PEMPRIL (PD-1), evocimab (PD-1/VEGF, AK112), Lefalimab (CD47, AK117), zoslizumab (CD73, AK119), proximab (VEGFR-2, AK109), AK127 (TIGIT), and AK115 ( NGF), covering a wide range of indications including hematological tumors and solid tumors
.
In the field of autoimmune diseases, Akeso also has a rich product pipeline, including erodizumab (IL-12/IL-23, AK101), gumochimab (IL-17, AK111) and mandocimab (IL-4R, AK120).

In addition, Akeso's innovative products in the field of metabolic therapy include inusimab (PCSK9, AK102),
which entered into a joint venture agreement with Dongrui Pharmaceutical.
Keji Pharmaceutical was active in early trading, rising about 6%.

For Keji Pharmaceutical, on the news, a few days ago, Keji Pharmaceutical announced that the company and the State Key Laboratory of Oncogenes and Related Genes of Shanghai Cancer Institute jointly developed a new treatment technology
that can significantly increase the activity of T cells against solid tumors.
The study was recently published in Molecular Therapy
.
Previously, CSC commented that Keji Pharmaceutical is an innovative pharmaceutical company focusing on CAR-T cell therapy, and its core products CT053 and CT041 have been successfully developed and are expected to be gradually commercialized; At the same time, the company has a variety of technical platforms to solve the problem of CAR-T therapy, and is expected to make continuous breakthroughs
in solid tumors in the future.
Considering that the company is about to commercialize, while deeply cultivating cell therapy, and has good growth, it is first given a "buy" rating
.
Shandong Xinhua Pharmaceutical shares rose 7.
12% as of 09:52 on January 3 and are now trading at HK$8.
73, up HK$0.
58
.
12.
13 million shares were traded, involving 103.
1 million yuan
.
According to the data, Shandong Xinhua Pharmaceutical Co.
, Ltd.
is mainly engaged in the development, manufacture and sales of chemical APIs, preparations, pharmaceutical intermediates and other products, as a chemical synthetic pharmaceutical enterprise, the company is the world's important antipyretic analgesic manufacturers and export base, domestic important cardiovascular and cerebrovascular, anti-infective, central nervous system and other production enterprises
.
Analysts pointed out that ursodeoxycholic acid and the recent ibuprofen have put Xinhua Pharmaceutical on the cusp
.
It is conceivable that products such as ibuprofen will bring considerable benefits
to Xinhua Pharmaceutical in the short term.
InnoCare recently announced that the combination therapy of its CD19 monoclonal antibody Tafasitamab and the antitumor drug lenalidomide has been approved for marketing in
Hong Kong, China.
It is reported that this is another commercial report card
submitted by InnoCare to the market after the BTK inhibitor orelabrutinib.
According to the data, Tafasitamab is a product authorized by InnoCare from the US biopharmaceutical company Incyte in August 2021, and its combination therapy has previously been conditionally approved by the US FDA and the European Medicines Agency for the treatment of patients with relapsed/refractory diffuse large B-cell lymphoma
who are not suitable for autologous stem cell transplantation 。 It is reported that after Tafasitamab is listed in Hong Kong, the next step is to accelerate bridging trials in the mainland to strive for early approval, and InnoCare's TYK2, pan-FGFR and other drug candidates have entered the key clinical stage and are expected to achieve an updated breakthrough
in 2023.
For Federal Pharmaceutical, on the news, recently, Minsheng Securities suggested paying attention to the investment opportunities
of anti-infective drugs under the optimization of epidemic prevention policies.
On the current strong demand base, there is room for improvement brought by the release of production capacity and the expectation of price increases, and it is recommended to focus on many companies
such as Federal Pharmaceutical.
According to combing, Federal Pharmaceutical is a domestic API and preparation manufacturer
among the main anti-infective drugs such as cephalosporins, penem and amoxicillin.
In the first half of this year, the company achieved sales of antibiotic products of about 3.
490 billion yuan, with total revenue accounting for 67.
35%.

Disclaimer: Under no circumstances does the information or opinions expressed herein constitute investment advice
to anyone.